Literature DB >> 29973859

Serious Mental Illness in Heavy Drinkers Is Associated with Poor Treatment Outcomes in Outpatients with Co-occurring Disorders.

Oladunni Oluwoye1,2, Emily Leickly1,2, Jordan Skalisky1,2, Sterling McPherson2,3,4, Katherine Hirchak1,2, Debra Srebnik5, John M Roll2,3, Richard K Ries5, Michael G McDonell1,2,3.   

Abstract

The objective of this study was to determine whether the interaction between type of serious mental illness (SMI) and pre-treatment drinking severity, assessed by ethyl glucuronide (EtG), predicts EtG-positive urine samples submitted during treatment in outpatients with co-occurring alcohol dependence and SMI. Seventy-nine participants were randomized to treatment-as-usual or treatment-as-usual and contingency management (CM) targeting alcohol abstinence. Generalized estimating equations were used to assess the interaction of pre-treatment drinking (heavy drinking or light drinking) and SMI diagnosis (major depression, bipolar, or schizophrenia-spectrum disorders) across a 12-week treatment period. In the overall sample, the interaction of drinking severity and SMI diagnosis (p = 0.006) was associated with alcohol abstinence. Exploratory analyses of the interaction term among participants randomized to CM (n = 40; p = 0.008) were associated with alcohol abstinence during CM. Type of SMI diagnosis was associated with treatment outcomes in individuals who engaged in heavy drinking, but not light drinking, prior to treatment.

Entities:  

Keywords:  Alcohol treatment; Co-occurring disorders; Contingency management; Ethyl glucuronide; Heavy drinking; Serious mental illness

Year:  2017        PMID: 29973859      PMCID: PMC6027641     

Source DB:  PubMed          Journal:  Int J Ment Health Addict        ISSN: 1557-1874            Impact factor:   3.836


  18 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

Review 2.  Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature.

Authors:  Julie Kreyenbuhl; Ilana R Nossel; Lisa B Dixon
Journal:  Schizophr Bull       Date:  2009-06-02       Impact factor: 9.306

3.  Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients.

Authors:  Frank N Angelo; Michael G McDonell; Michael R Lewin; Debra Srebnik; Jessica Lowe; John Roll; Richard Ries
Journal:  Drug Alcohol Depend       Date:  2012-12-27       Impact factor: 4.492

4.  Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients.

Authors:  Michael G McDonell; Jordan Skalisky; Emily Leickly; Sterling McPherson; Samuel Battalio; Jenny R Nepom; Debra Srebnik; John Roll; Richard K Ries
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

5.  A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness.

Authors:  Michael G McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Debra Srebnik; Frank Angelo; Roger Vilardaga; Jenny R Nepom; John M Roll; Richard K Ries
Journal:  Am J Psychiatry       Date:  2017-01-31       Impact factor: 18.112

6.  A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.

Authors:  Alan S Bellack; Melanie E Bennett; Jean S Gearon; Clayton H Brown; Ye Yang
Journal:  Arch Gen Psychiatry       Date:  2006-04

7.  The role of psychiatric disorders in predicting drug dependence treatment outcomes.

Authors:  Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

Review 8.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 9.  Clinical treatment matching models for dually diagnosed patients.

Authors:  R Ries
Journal:  Psychiatr Clin North Am       Date:  1993-03

10.  Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial.

Authors:  Christine Barrowclough; Gillian Haddock; Til Wykes; Ruth Beardmore; Patricia Conrod; Tom Craig; Linda Davies; Graham Dunn; Emily Eisner; Shôn Lewis; Jan Moring; Craig Steel; Nicholas Tarrier
Journal:  BMJ       Date:  2010-11-24
View more
  3 in total

1.  Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.

Authors:  João M Castaldelli-Maia; André Malbergier; Adriana B P de Oliveira; Ricardo A Amaral; André B Negrão; Priscila D Gonçalves; Antonio Ventriglio; Domenico de Berardis; Juliana de Antonio; Isabela Firigato; Gilka J F Gattás; Fernanda de Toledo Gonçalves
Journal:  Biomolecules       Date:  2021-10-10

2.  Psychosocial interventions for people with both severe mental illness and substance misuse.

Authors:  Glenn E Hunt; Nandi Siegfried; Kirsten Morley; Carrie Brooke-Sumner; Michelle Cleary
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

Review 3.  A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies.

Authors:  Sterling M McPherson; Ekaterina Burduli; Crystal Lederhos Smith; Jalene Herron; Oladunni Oluwoye; Katherine Hirchak; Michael F Orr; Michael G McDonell; John M Roll
Journal:  Subst Abuse Rehabil       Date:  2018-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.